MarketLine  

All articles by MarketLine  

1. The race to buy gene therapy developers is intensifying

   The recent acquisitions of Spark Therapeutics and Nightstar Rx signals the race to acquire gene therapy delivery platforms is well…
   Read More…

   14 Mar
2. Trump administration proposal may neuter America’s tapeworm PBMs

   The United States Department of Health and Human Services has proposed new limitations on pharmacy benefit manager (PBM) rebates. The…
   Read More…

   26 Feb
3. Why Sangamo’s shares tanked by 48%

   The collapse Sangamo Therapeutics’ shares, by 48%, after results of its Champions trial were released has raised questions about the…
   Read More…

   8 Feb
4. Can BMS make a success of its Celgene acquisition?

   Pharmaceutical company Bristol-Myers Squibb (BMS) has bought US biotech Celgene for $74bn as it seeks to leave its troubles behind….
   Read More…

   10 Jan